Physician profile
John H Beckerman
NPI 1578556452
$3,245.52
in general payments reported to CMS, 2019-2025
22 companies · $631 in 2025
The $631 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $312 · 2021: $512 · 2022: $434 · 2023: $602 · 2024: $305 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $472.92 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $468.87 | 2020-2022 | |
| Sanofi Pasteur INC. | $360.53 | 2019-2025 | |
| Corium, LLC | $341.92 | 2022-2025 | Azstarys |
| Pfizer INC. | $300.58 | 2020-2023 | |
| Ars Pharmaceuticals Operations, INC. | $169.32 | 2025 | Neffy |
| Tris Pharma INC | $162.83 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $154.62 | 2019-2021 | |
| Shire North American Group INC | $139.63 | 2019 | |
| Vyne Pharmaceuticals INC. | $112.08 | 2020 | |
| Genentech USA, INC. | $77.03 | 2020-2021 | |
| Alk-Abello, INC | $75.06 | 2023 | Odactra, Ragwitek, Grastek |
| Adlon Therapeutics L.P. | $71.08 | 2019-2020 | |
| Noven Therapeutics, LLC | $52.95 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $52.02 | 2025 | Relexxii |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $47.34 | 2019-2022 | |
| Cranial Technologies, INC | $47.05 | 2019-2022 | |
| Seqirus USA INC | $43.34 | 2025 | Flucelvax |
| Ironshore Pharmaceuticals INC. | $31.99 | 2019 | |
| Biomarin Pharmaceutical INC. | $26.58 | 2023 | Voxzogo 1.2mg |
| Supernus Pharmaceuticals, INC. | $23.15 | 2025 | Qelbree |
| Dermira, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.